miRagen raises $41 series C

MicroRNA company miRagen Therapeutics Inc. raised $41 million in a series C round co-led by MRL Ventures and JAFCO. Other new investors Brace Pharma Capital and MP Healthcare Venture Management joined existing investors Atlas Venture, Boulder Ventures, Remeditex Ventures and Amgen Ventures. Undisclosed existing investors also participated.

miRagen said it will use the proceeds to put two products into the clinic this year. These include MRG-106, an antagonist of miR-155 to treat hematological malignancies, and MRG-201, an agonist of miR-29b to treat pathological fibrosis. ...